187 results on '"Merali, S"'
Search Results
2. Countering Islamophobia in Europe
3. Distinct Neutrophil Phenotypes in Sepsis Patients and Associations With Clinical Outcomes and Sources of Sepsis
4. Circadian rhythm dysfunction: a novel environmental risk factor for Parkinson’s disease
5. A randomized, cross-over study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of milvexian with single and dual antiplatelet therapy in healthy participants
6. Bovine serum amine oxidase and spermine cause apoptosis in cancer cells detected by flow cytometry, real time RT-PCR and proteomic analyses
7. Functional analysis of the -2548G/A leptin gene polymorphism in breast cancer cells
8. Circadian rhythm dysfunction: a novel environmental risk factor for Parkinson’s disease
9. Chronic behavioral stress exaggerates motor deficit and neuroinflammation in the MPTP mouse model of Parkinson’s disease
10. Characterizing community exercise programs delivered by recreation providers for people with neurological conditions: a scoping review
11. Prioritizing challenges and solutions to the implementation of task-oriented community exercise programs for people with balance and mobility limitations
12. INHIBITION OF CALPAINS PREVENTS NEURONAL AND BEHAVIORAL DEFICITS IN A MPTP MICE MODEL OF PARKINSON'S DISEASE
13. Claiming Multiple Identities
14. Stress Incontinence in Women; a Pilot Study Comparing the Miniarc Single Incision Sling System to the Monarc Transobturator Sling System
15. 799 VAD Competent or VAD Aware?
16. Prevention of Doxorubicin Cardiopathic Changes by a Benzyl Styryl Sulfone in Mice
17. S-Adenosylmethionine Levels in the Diagnosis of Pneumocystis carinii Pneumonia in Patients with HIV Infection
18. -Adenosylmethionine and
19. Antifungal and Anti-inflammatory Activity of the Genus Echinacea
20. Antiviral Activity of Characterized Extracts fromEchinaceaspp. (Heliantheae: Asteraceae) againstHerpes simplexVirus (HSV-I)
21. Insecticidal activity of Piper tuberculatum Jacq. extracts: synergistic interaction of piperamides
22. Continuous infusion of DL-alpha-difluoromethylornithine and improved efficacy against a rat model of Pneumocystis carinii pneumonia
23. Trophozoite elimination in a rat model of Pneumocystis carinii pneumonia by clinically achievable plasma deferoxamine concentrations
24. Polyamine content of Pneumocystis carinii and response to the ornithine decarboxylase inhibitor DL-alpha-difluoromethylornithine
25. Clinically achievable plasma deferoxamine concentrations are therapeutic in a rat model of Pneumocystis carinii pneumonia
26. Response of rat model of Pneumocystis carinii pneumonia to continuous infusion of deferoxamine
27. Personalizing biomarker strategies in heart failure with galectin-3.
28. Heightened endoplasmic reticulum stress in the lungs of patients with chronic obstructive pulmonary disease: the role of Nrf2-regulated proteasomal activity.
29. Susceptibility of Pneumocystis carinii to artemisinin in vitro
30. Inhibition of Pneumocystis carinii dihydropteroate synthetase by sulfa drugs
31. Oxidosqualene Cyclase Inhibitors as Antimicrobial Agents
32. Antiviral Activity of Characterized Extracts from Echinacea spp. (Heliantheae: Asteraceae) against Herpes simplex Virus (HSV-I).
33. S-adenosylmethionine and Pneumocystis carinii.
34. Pneumocystis carinii polyamine catabolism.
35. Polyamine analysis using N-hydroxysuccinimidyl-6-aminoquinoyl carbamate for pre-column derivatization
36. Supervision: what the foundation year doctor needs to know.
37. Long-term outcome of isolated coronary artery bypass surgery in patients with severe left ventricular dysfunction.
38. S-adenosylmethionine concentrations in diagnosis of Pneumocystis carinii pneumonia.
39. Sustained caloric restriction potentiates insulin action by activating prostacyclin synthase.
40. Absolute oral bioavailability of milvexian spray-dried dispersion formulation under fasted and fed conditions in healthy adult participants: An intravenous microtracer approach.
41. Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Rationale for Clinically Guided Dose Titration to Optimize Individual Response.
42. First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-986308: A Renal Outer Medullary Potassium Channel Inhibitor.
43. Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titration.
44. Safety, tolerability, pharmacokinetics and pharmacodynamics of milvexian with aspirin and/or clopidogrel in healthy participants.
45. Effect of Activated Charcoal on Mavacamten Pharmacokinetics in Healthy Participants.
46. Recommendation of mavacamten posology by model-based analyses in adults with obstructive hypertrophic cardiomyopathy.
47. PAR4 Antagonism in Patients With Coronary Artery Disease Receiving Antiplatelet Therapies.
48. Distinct functional neutrophil phenotypes in sepsis patients correlate with disease severity.
49. COVID-19 outcome trends by vaccination status in Canada, December 2020-January 2022.
50. A scoping review of the globally available tools for assessing health research partnership outcomes and impacts.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.